- Updated: GSK reveals three-year blueprint to cut costs and propel R&DJust a little over six months into his tenure as CEO at GSK, Luke Miels is making his mark. The drugmaker on Tuesday outlined plans for a three-year cost-cutting initiative, the launch of at least ...Endpoints · 10h ago↗ source
- Apnimed eyes up to $160M IPO to prep for sleep apnea drug launchIf the offering closes, Apnimed will join the 2026 IPO class that has already far surpassed last year’s total.BioSpace · 10h ago↗ source
- Oak Hill takes SPAC track to Nasdaq with Roche asset in towOak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.BioSpace · 10h ago↗ source